Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 4
Submit an article Journal homepage
2,333
Views
9
CrossRef citations to date
0
Altmetric
Cardiovascular Medicine

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis

Lisa Aniek de JongUnit of PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Groningen, the Netherlands; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-8814-0670
ORCID Icon,
Judith J. Gout-ZwartDepartment of Nephrology, University of Groningen, University Medical Center Groningen (UMCG), the Netherlands; ;Asc Academics, Groningen, the Netherlands;
,
Marina van den BoschBayer, Mijdrecht, the Netherlands;
,
Mike KoopsUnit of PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Groningen, the Netherlands;
&
Maarten J. PostmaUnit of PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Groningen, the Netherlands; ;Institute for Science in Healthy Aging & healthcaRE (SHARE), University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands; ;Department of Health Sciences, University of Groningen, University Medical Center Groningen (UMCG), the NetherlandsORCID Iconhttp://orcid.org/0000-0002-6306-3653
ORCID Icon
Pages 306-318 | Received 07 Aug 2018, Accepted 18 Dec 2018, Published online: 15 Jan 2019

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Tanja Fens, Lisa de Jong, Bregt Kappelhoff, Cornelis Boersma & Maarten J. Postma. (2023) Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran. Journal of Market Access & Health Policy 11:1.
Read now

Articles from other publishers (8)

Sabrina Kepka, Elena-Mihaela Cordeanu, Kevin Zarca, Anne-Sophie Frantz, Patrick Ohlmann, Emmanuel Andres, Pascal Bilbault, Isabelle Durand-Zaleski & Dominique Stephan. (2023) A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry. Medicina 59:1, pages 181.
Crossref
Felix E. de Jongh, Reva Efe, Kirsten H. Herrmann & Jelle A. Spoorendonk. (2022) Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands. International Journal of Breast Cancer 2022, pages 1-12.
Crossref
Tianyu Feng, Zhou Zheng, Shang Gao, Jiaying Xu, Pen Cao, Huanhuan Jia & Xihe Yu. (2022) Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease. Frontiers in Pharmacology 13.
Crossref
Z. Kevin Lu, Xiaomo Xiong, Taiying Lee, Jun Wu, Jing Yuan & Bin Jiang. (2021) Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis. Frontiers in Pharmacology 12.
Crossref
Synne G. Fronas, Anders E. A. DahmHilde S. WikCamilla T. JørgensenJostein GleditschNezar RaoufRené HolstFrederikus A. Klok & Waleed Ghanima. (2020) Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis. Blood Advances 4:11, pages 2468-2476.
Crossref
Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier, Mondher Toumi, Emilie Clay & Pierre Levy. (2020) Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. PLOS ONE 15:1, pages e0225301.
Crossref
Alejandro Isidoro Pérez Cabeza, Jaime Nevado Portero, Martín Ruiz Ortiz, Luis Tercedor Sánchez, Rafael Vázquez García, José Luis Delgado Prieto, Alejandro Recio Mayoral, Manuel Beltrán Robles, Francisco Moniche, Javier Torres Llergo & Jaime Masjuán. (2020) Recomendaciones de expertos en la mejora de la prevención efectiva del ictus isquémico en la fibrilación auricular no valvular: papel del rivaroxabán. Revista Española de Cardiología Suplementos 20, pages 21-29.
Crossref
Aapeli Leminen, Mikko Pyykönen, Juho Tynkkynen, Markku Tykkyläinen & Tiina Laatikainen. (2019) Modeling patients’ time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants. BMC Health Services Research 19:1.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.